Fineline Cube

Follow:
14475 Articles
European Commission Grants Conditional Approval to Ipsen's Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations
CompanyDrug

European Commission Grants Conditional Approval to Ipsen’s Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology
CompanyMedical Device

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology

FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2–11 Years
CompanyDrug

FDA Approves Sanofi-Regeneron’s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2–11 Years

CompanyDrug

China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines

FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026
CompanyDrug

FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026

Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Merck's Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
CompanyDrug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

CompanyDeals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

CompanyDrug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
CompanyDeals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

CompanyDrug

Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials

Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness
Company

Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness